Reported Sunday, Johnson & Johnson Reveals New Data on TAR-200 for Bladder Cancer Treatment
Reported Sunday, Johnson & Johnson Reveals New Data on TAR-200 for Bladder Cancer Treatment
週日報道，強生公司披露了有關TAR-200用於膀胱癌治療的新數據
Johnson & Johnson (NYSE:JNJ) announced today additional results from the pivotal Phase 2b SunRISe-1 study, supporting the safety and efficacy profile of investigational TAR-200 for the treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (HR-NMIBC). New data were featured in a late-breaking oral presentation at the European Society of Medical Oncology (ESMO) 2024 Congress (Abstract #LBA85).
強生（NYSE：JNJ）今天宣佈了關鍵的第20億SunRISe-1研究的額外結果，支持TAR-200治療乙型卡介苗不應答的高風險非肌層侵犯性膀胱癌（HR-NMIBC）患者的安全性和療效概況。新數據在2024年歐洲醫學腫瘤學會（ESMO）大會上的破題口頭報告（摘要＃LBA85）中進行了介紹。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。